COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,797 Articles (22,527 medRxiv, 8,270 bioRxiv)

Most recent first Previous |  Page 2937: Articles 29361-29370  | Next

Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1
Li, Y., Wang, H., Tang, X., Ma, D., Du, C., Wang, Y., Pan, H., Zou, Q., Zheng, J., Xu, L., Farzan, M., Zhong, G.
10.1101/2020.04.10.032342 — Posted: 2020-04-11 Discussion: Onsite
De novo design of high-affinity antibody variable regions (scFv) against the SARS-CoV-2 spike protein
Boorla, V. S., Chowdhury, R., Maranas, C. D.
10.1101/2020.04.09.034868 — Posted: 2020-04-11
Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of RBD mutant with lower ACE2 binding affinity
JIA, Y., Shen, G., Zhang, Y., Huang, K.-S., Ho, H.-Y., Hor, W.-S., Yang, C.-H., Li, C., Wang, W.-L.
10.1101/2020.04.09.034942 — Posted: 2020-04-11 Discussion: Onsite | Offsite
Comparative ACE2 variation and primate COVID-19 risk
Melin, A. D., Janiak, M. C., Marrone, F., Arora, P. S., Higham, J. P.
10.1101/2020.04.09.034967 — Posted: 2020-04-11 Discussion: Onsite
Projected early spread of COVID-19 in Africa
Pearson, C. A., Van Schalkwyk, C., Foss, A. M., O'Reilly, K. M., CMMID COVID-19 working group, , SACEMA 10 Modelling and Analysis Response Team, , Pulliam, J. R. C.
10.1101/2020.04.05.20054403 — Posted: 2020-04-10 Discussion: Offsite
Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Lane, J. C., Weaver, J., Kostka, K., Duarte-Salles, T., Abrahao, M. T., Alghoul, H., Alser, O., Alshammari, T. M., Biedermann, P., Burn, E., Casajust, P., Conover, M., Culhane, A. C., Davydov, A., DuVall, S. L., Dymshyts, D., Fernández Bertolín, S., Fišter, K., Hardin, J., Hester, L., Hripcsak, G., Kent, S., Khosla, S., Kolovos, S., Lambert, C. G., ver der Lei, J., Londhe, A. A., Lynch, K. E., Makadia, R., Margulis, A. V., Matheny, M. E., Mehta, P., Morales, D. R., Morgan-Stewart, H., Mosseveld, M., Newby, D., Nyberg, F., Ostropolets, A., Park, R. W., Prats-Uribe, A., Rao, G. A., Reich, C., Reps, J., Rijnbeek, P., Sathappan, S. M., Schuemie, M., Seager, S., Sena, A., Shoaibi, A., Spotnitz, M., Suchard, M. A., Swerdel, J., Torre, C. O., Vizcaya, D., Wen, H., de Wilde, M., You, S. C., Zhang, L., Zhuk, O., Ryan, P., Prieto-Alhambra, D.
10.1101/2020.04.08.20054551 — Posted: 2020-04-10 Discussion: Onsite | Offsite
A model to predict COVID-19 epidemics withapplications to South Korea, Italy, and Spain
Webb, G. F., Magal, P., Liu, Z., Seydi, O.
10.1101/2020.04.07.20056945 — Posted: 2020-04-10
Evaluation of nine commercial SARS-CoV-2 immunoassays
Lassauniere, R., Frische, A., Harboe, Z. B., Nielsen, A. C., Fomsgaard, A., Krogfelt, K. A., Jorgensen, C. S.
10.1101/2020.04.09.20056325 — Posted: 2020-04-10 Discussion: Onsite | Offsite
Homologous protein domains in SARS-CoV-2 and measles, mumps and rubella viruses: preliminary evidence that MMR vaccine might provide protection against COVID-19
Franklin, R., Young, A., Neumann, B., Fernandez, R., Joannides, A., Reyahi, A., Modis, Y.
10.1101/2020.04.10.20053207 — Posted: 2020-04-10 Discussion: Onsite | Offsite
The effectiveness of non-pharmaceutical interventions in containing epidemics: a rapid review of the literature and quantitative assessment
Cheatley, J., Vuik, S., Devaux, M., Scarpetta, S., Pearson, M., Colombo, F., Cecchini, M.
10.1101/2020.04.06.20054197 — Posted: 2020-04-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).